ProCE Banner Activity

PALOMA: Phase Ib Trial of Subcutaneous Amivantamab Given Every 4 Wk in Patients With Advanced Solid Tumors

Conference Coverage
Slideset

In this analysis of the phase Ib PALOMA trial, the identified dose of amivantamab SC Q4W was associated with similar exposure and a lower rate of IRRs vs the approved IV dose in a small cohort of patients with advanced solid tumors, including lung cancers.

Released: May 02, 2024

Expiration: May 01, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc